1-8 of 8
Mark S Hertzberg, MD, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

B2M Gene Expression Reflects an Immunologically Active Tumor Microenvironment in DLBCL

Clare Gould, Colm Keane, MD, Valentine Murigneux, M.Sc., Harald Oey, Jonathan Ellis, PhD, Simone Birch, MBBS, Jay Gunawardana, PhD, Dipti Talaulikar, Mark S. Hertzberg, MD PhD, Kimberley Jones, Maher K. Gandhi, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2778.
https://doi.org/10.1182/blood-2019-126537
Published: 2019
Journal Articles

Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCL

Charles Macaulay, MSc, BA, Stefan Alig, MD, David M. Kurtz, MD PhD, Michael C. Jin, BS, Stephen Opat, Joanne Soo, MD, Brian Sworder, MD PhD, Mark S. Hertzberg, MD PhD, Maher K. Gandhi, PhD, Maximilian Diehn, MD PhD, Ash A. Alizadeh, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1600.
https://doi.org/10.1182/blood-2019-131278
Published: 2019
Journal Articles

Early Switch to Nilotinib Does Not Overcome the Adverse Outcome for CML Patients Failing to Achieve Early Molecular Response On Imatinib, Despite Excellent Overall Outcomes in the TIDEL II Trial

David T Yeung, BSc, MBBS, FRACP, FRCPA, Michael Philip Osborn, MBBS, Deborah L White, PhD, Susan Branford, PhD, Michael Kornhauser, Cassandra Slader, PhD, Samar Issa, MBChB, FRACP, FRCPA, Devendra K. Hiwase, MBBS, MD, PhD, FRACP, FRCPA, Mark S. Hertzberg, MD, PhD, Anthony P. Schwarer, MD, Robin Filshie, PhD, FRACP, Christopher K Arthur, MBBS, FRACP, FRCPA, Yiu Lam Kwan, MBBS FRACP FRCPA, Cecily J Forsyth, FRACP, FRCPA, David Ross, MBBS, PhD, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy P. Hughes, MD, MBBS, on Behalf Of ALLG
Journal: Blood
Blood (2012) 120 (21): 3771.
https://doi.org/10.1182/blood.V120.21.3771.3771
Published: 2012
Journal Articles

Bortezomib-Based Induction Overcomes Effect of 1q Amplification On Response in Newly-Diagnosed Myeloma and Results in Similar 2 Year Event-Free Survival

Douglas E Joshua, MBBS, DPhil, Mark S Hertzberg, MD, PhD, Bradley Auguston, Andrew Spencer, MD, Noemi Horvath, MB, ChB, FRACP, FRCPA, John Bashford, MBBS, FRACP, FRCPA, Lynda J Campbell, Eleanor Ashurst, Jacquelyn Wade, Michael C. Copeman, DPhil, FRACP, Belinda E Butcher, BSc(Hons) MBiostat PhD, Miles Prince, MD, FRACP, FRCPA
Journal: Blood
Blood (2012) 120 (21): 4065.
https://doi.org/10.1182/blood.V120.21.4065.4065
Published: 2012
Journal Articles

Upfront Imatinib Therapy in CML Patients with Rapid Switching to Nilotinib for Failure to Achieve Molecular Targets or Intolerance Achieves High Overall Rates of Molecular Response and a Low Risk of Progression - An Update of the TIDEL-II Trial

David T. Yeung, BSc, MBBS, FRACP, FRCPA, Michael Osborn, MBBS, FRACP, FRCPA, Deborah L. White, PhD. FFSc(RCPA), Susan Branford, PhD, Michael Kornhauser, Cassandra Slader, PhD, Samar Issa, FRACP, FRCPA, Devendra K Hiwase, MBBS, MD, PhD, FRACP, FRCPA, Mark S. Hertzberg, MD, PhD, Anthony P. Schwarer, MD, Robin Filshie, PhD, FRACP, Christopher K Arthur, MBBS, FRACP, FRCPA, Yiu Lam Kwan, MBBS FRACP FRCPA, Cecily J Forsyth, FRACP, FRCPA, David Ross, MBBS, PhD, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy P. Hughes, MD, MBBS, FRACP, FRCPA
Journal: Blood
Blood (2011) 118 (21): 451.
https://doi.org/10.1182/blood.V118.21.451.451
Published: 2011
Journal Articles

Monocytes Are Associated with Impaired T-Cell Immunity and Residual Interim-PET/CT Avidity After 4 Cycles of CHOP-R In Patients with High-Risk DLBCL,

Maher K Gandhi, PhD, FRACP, FRCPath, FRCP, Mark S. Hertzberg, MD, PhD, Erica Han, John F. Seymour, MD, PhD, Rodney Hicks, MB BS, MD, FRACP, Devinder S Gill, MD, Colm Keane, MB BCh BAO MSc MRCPI FRCPath, Pauline Crooks, Kristen Radford, PhD, Frank Vari, Phd
Journal: Blood
Blood (2011) 118 (21): 3673.
https://doi.org/10.1182/blood.V118.21.3673.3673
Published: 2011
Journal Articles

Selective Escalation of Imatinib Therapy and Early Switching to Nilotinib In De Novo Chronic Phase CML Patients: Interim Results From the TIDEL-II Trial

David T. Yeung, MBBS, Michael Osborn, MBBS, FRACP, FRCPA, Deborah L. White, PhD, Susan Branford, PhD, Lauren Haswell, MSci, Cassandra Slader, PhD, Samar Issa, FRACP, FRCPA, Devendra K. Hiwase, MBBS, PhD, Mark S. Hertzberg, MD, PhD, Anthony P. Schwarer, MD, Robin Filshie, PhD, FRACP, Christopher K. Arthur, MBBS, Yiu Lam Kwan, MBBS, FRACP, FRCPA, Cecily J. Forsyth, FRACP, FRCPA, David M. Ross, MBBS, PhD, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy Hughes, MD, MBBS, on Behalf Of ALLG
Journal: Blood
Blood (2010) 116 (21): 209.
https://doi.org/10.1182/blood.V116.21.209.209
Published: 2010
Journal Articles

Maintaining Imatinib ≥600 Mg Daily in the First 12 Months of Chronic Phase CML Treatment Is Associated with Superior Event-Free Survival at 5 Years.

Michael P Osborn, Susan Branford, PhD, Deborah L White, PhD, John F Seymour, PhD, Ruth Columbus, Kerry Taylor, Christopher Arthur, Anthony Schwarer, Julian Cooney, MD, Michael F Leahy, Philip Rowlings, John Catalano, MD, Mark S Hertzberg, MD, PhD, Robin Filshie, PhD, Anthony K Mills, Keith Fay, Simon Durrant, Henry Januszewicz, David Joske, MD, Craig Underhill, Scott Dunkley, PhD, Andrew Grigg, Timothy P Hughes, MD
Journal: Blood
Blood (2009) 114 (22): 1125.
https://doi.org/10.1182/blood.V114.22.1125.1125
Published: 2009